Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
RA Capital Management has completed the acquisition of Research Alliance III, a healthcare services other business in New York, for $75 million. The biotech SPAC is structured to merge into an operating biotechnology company spanning drug development and commercialization, diagnostics, and healthcare technology and services. RA Capital Management acquisitions in healthcare M&A focus on identifying a platform acquisition target that can scale commercialization and clinical programs. The platform acquisition is a private equity acquisition via a blank-check vehicle that sold 7.5 million shares at $10 on Nasdaq under ticker RACC, with an expanded share offering and a stated intent to pursue a China-based healthcare deals NY target.
Filed under
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026